RRD characteristics and visual outcomes

Article

In this article, Mr Dogramaci highlights a recent study in which he and his colleagues examined the characteristics of RRD and the relationship these characteristics have on visual outcome.

The study

"Data from all patients attending a single author's (THW) vitreoretinal surgery service were prospectively entered into an electronic patient record (VITREOR, Microsoft Access, available with the book 'Vitreoretinal Surgery', published by Springer)," said Mr Dogramaci. "This electronic patient record requires recording of retinal detachment characteristics and digital drawings of the RRD, as well enabling the recording of postoperative outcomes; it is therefore a valuable tool for audit and clinical governance."

Mr Dogramaci explained that in patients, who developed bilateral RRD, the team only included the first eye in the study. Exclusion criteria also included, patients under 40 years of age (to avoid the influence of RRD from young myopes with atrophic holes and vitreous attached), or with aphakia, anterior chamber lens implant, giant retinal tear, retinal dialysis, macular hole-related RRD, retinoschisis-related RRD and dislocated lens nucleus during cataract surgery.

Retinal drawing

Any break present in any of the four quadrants was recorded. "The presence of inferior breaks were recorded, specifically noting their location in o'clock hours and whether they were in flat or detached retina. Inferior breaks can present particular challenges in surgical management, as compared with breaks elsewhere," Mr Dogramaci stressed.

Success

Success was defined in three categories at final follow-up:

1. Primary success with a fully attached retina without intraocular tamponade with one planned procedure (excluding oil removal) or two procedures if a planned delayed retinectomy was performed for PVR.

2. Secondary success when a fully flat retina even with silicone oil in situ was achieved outside those parameters described in 1.

3. Final failure with any area of retinal detachment at final follow-up.

"For most of the statistical comparisons, category 1 (primary success) have been compared to a combination of both 2 and 3 (primary failure). The primary outcome measure was the achievement of 6/9 vision (LogMAR 0.18) or better," continued Mr Dogramaci. "To determine the effect of duration of visual loss on visual recovery for patients with and without evidence of a clinically detached fovea (fovea off), patients with primary success of surgery and no PVR were further analysed."

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Alfredo Sadun, MD, PhD, chief of Ophthalmology at the Doheny Eye Institute, University of California Los Angeles, shared exciting new research with the Eye Care Network during the Association for Research in Vision and Ophthalmology (ARVO) meeting on the subject of Leber hereditary optic neuropathy (LHON).
At this year's Association for Research in Vision and Ophthalmology (ARVO) meeting in Salt Lake City, Utah, Nitish Mehta, MD, shared highlights from his research documenting real-world results of aflibercept 8 mg for patients with diabetic macular oedema.
ARVO 2025: Anat Loewenstein, MD, shares data from herself and her colleagues on meeting needs of patients with diabetic retinopathy
A photo of Seville, Spain, with the Congress on Controversies in Ophthalmology logo superimposed on it. Image credit: ©francovolpato – stock.adobe.com; logo courtesy COPHy
Anat Loewenstein, MD, Professor and Director, Department of Ophthalmology, Tel Aviv Medical Center, discusses the Congress on Controversies in Ophthalmology (COPHy)
Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
Charles Wykoff, MD, PhD, discusses his Floretina ICOOR presentation topic, retinal non-perfusion in diabetic retinopathy, with David Hutton, editor of Ophthalmology Times
Quan Dong Nguyen, MD, MSc, of the Byers Eye Institute at Stanford University School of Medicine, discusses his presentation on Stargardt disease at the American Academy of Ophthalmology meeting
David Yorston, FRCS, FRCOphth, discusses his EURETINA keynote lecture
Related Content
© 2025 MJH Life Sciences

All rights reserved.